以下文章来源于阿基米德Biotech ，作者阿基米德君 阿基米德Biotech . 生物医药第三方独立观察，客观中立，深入浅出，松弛愉悦，写作纯为兴趣，不接广告 一个伟大的开端。 作者 | 阿基米德君 来源 | 阿基米德Biotech （ID：ArchimedesBiotech） 这个冬天太长了。在遥远的2021年夏天，所有人都不会想到医药下行周期会超过3年半，以致于最有耐心的坚守者也濒临崩溃。 参考率先见底的CDMO，当所有负面因素都充分入价后，任何细微的边际改善都将带来巨大弹性。从底部挣扎起来，药明康德反弹约 60% 药明生物反弹约110%，药明合联一度逼近历史新高。 不要指望惊天大逆转，但细微的边际改善是可期待的，这已经足矣。 2024Q4，全部公募基金对医药板块的持仓比例为8.58%，环比下降1.08pct，已超过2022Q3全部基金持仓的低点位（9.37%）， 下降至历史最低位置，意味着任何细微的增量资金都将带来弹性。 寒冰融化。在支付端，单一支付体系即将破局，多元化支付体系将在年内初步建立，而且在用药群众对药效日益关切的推动下，集 采、医保谈判有望转向控费与质控的平衡；在融资端，未盈利生物科技企业 ...

Investment Rating - The report assigns a "Buy" rating for the company, indicating significant potential for growth due to its successful transformation into an innovative pharmaceutical leader [5][8]. Core Insights - The company has made substantial progress in its transformation from a traditional generic drug manufacturer to a leader in innovative pharmaceuticals, focusing on four key therapeutic areas: oncology, liver disease, respiratory, and surgical/pain management [7][10]. - The impact of centralized procurement has largely dissipated, allowing for a rapid increase in the proportion of revenue from innovative drugs, with expectations of over 20 new drug approvals by 2025 [10][41]. - The company has a robust pipeline with 17 approved innovative products and over 70 in clinical development, which is expected to drive revenue growth significantly [10][38]. Summary by Sections 1. Accelerated Transformation of Traditional Pharma Leader - The company has been transitioning towards innovation-driven growth, with a focus on high clinical value products and a strong commercialization system [7][19]. - The financial performance has shown a notable improvement, with revenue for the first half of 2024 reaching RMB 15.87 billion, a year-on-year increase of 11.1% [10][30]. - The company is actively pursuing international expansion and strategic collaborations to enhance its innovative capabilities [41][42]. 2. Innovative Drug Pipeline Continues to Deliver - The oncology sector is a core focus, with multiple innovative drugs launched, including Anlotinib, which has shown promising sales potential [47][49]. - The company’s innovative product revenue reached RMB 99 billion in 2023, accounting for 38% of total revenue, with expectations to exceed 45% by 2025 [38][39]. - The company is also focusing on enhancing its research and development efficiency, with a significant increase in the proportion of innovative drug R&D expenses [10][28]. 3. Financial Forecast and Valuation - Revenue projections for 2024-2026 are estimated at RMB 289.04 billion, RMB 321.90 billion, and RMB 360.85 billion, with corresponding growth rates of 10.32%, 11.37%, and 12.10% [6][8]. - The forecasted net profit for the same period is RMB 49.00 billion, RMB 52.09 billion, and RMB 55.59 billion, with growth rates of 110.14%, 6.31%, and 6.70% respectively [6][8]. - The company is expected to trade at a price-to-earnings ratio of 11, 10, and 9 times for 2024, 2025, and 2026, respectively, indicating a favorable valuation compared to peers [8][10].

Core Viewpoint - The approval of the clinical trial application for TQ05105 by the FDA marks a significant milestone for the company, enabling it to conduct trials in the U.S. and potentially benefit more patients, showcasing the company's innovative drug development capabilities and international strategic efforts [1][2]. Group 1: Product Development - TQ05105 (Rovastinib) is a novel JAK/ROCK inhibitor developed by the company, aimed at treating chronic graft-versus-host disease (cGVHD), a major complication post-transplantation [1]. - The drug effectively inhibits JAK family kinase activity and ROCK kinase activity, suppressing the JAK/STAT signaling pathway and exhibiting anti-tumor activity while selectively inhibiting ROCK2 to restore immune balance [1]. - Previous studies in China indicated that TQ05105 has a 90.9% objective response rate in cGVHD patients, with 88.6% of patients reducing steroid dosage [1]. Group 2: Strategic Implications - The FDA's approval is seen as a testament to the company's exceptional drug innovation capabilities and a proactive step in its internationalization strategy [2]. - The company is accelerating multiple combination studies for TQ05105, including trials with BET inhibitors or BCL-2 inhibitors for treating high-risk myelofibrosis, with preliminary results appearing positive [2].

Core Viewpoint - The approval of TQ05105 for clinical trials by the FDA represents a significant advancement in the treatment of chronic graft-versus-host disease (cGVHD), highlighting the company's innovative capabilities and strategic international expansion [1][3]. Company Summary - The company, a leading player in the Hong Kong stock market, has received FDA approval for its JAK/ROCK inhibitor TQ05105, aimed at treating cGVHD, a common complication post-transplantation with incidence rates between 30% and 70% [1][2]. - TQ05105 is a novel JAK/ROCK inhibitor that effectively suppresses JAK family kinase activity and ROCK enzyme activity, demonstrating anti-tumor activity and a high objective response rate of 90.9% in cGVHD patients [2][3]. - The company is also advancing TQ05105 for the treatment of myelofibrosis (MF), with regulatory approval obtained in China, indicating a broader therapeutic potential for this rare myeloid tumor [3][4]. Industry Summary - Chronic graft-versus-host disease is a major complication following transplantation, often leading to severe impacts on patients' quality of life due to its diverse clinical manifestations and prolonged course [1][2]. - The approval of TQ05105 for clinical trials in the U.S. is expected to provide more treatment opportunities for patients, reflecting the industry's ongoing efforts to innovate and address unmet medical needs in hematological conditions [3]. - The company is also exploring additional clinical research avenues for TQ05105, including its use in combination with BET inhibitors or BCL-2 inhibitors for treating myelofibrosis, which is recognized in the national disease catalog in China [4].

Core Viewpoint - China Biologic Products announced positive interim results from a Phase III clinical study of its independently developed Anlotinib hydrochloride capsules combined with Pembrolizumab injection for advanced hepatocellular carcinoma, meeting predefined efficacy standards for progression-free survival (PFS) and overall survival (OS) [1] Group 1: Clinical Study Results - The study included 649 patients with advanced liver cancer [1] - The median PFS for the experimental group was 6.9 months, while the OS was 16.5 months, both significantly better than the control group [1] Group 2: Regulatory Actions - Based on these positive results, the company has applied to the National Medical Products Administration of China for a new indication approval [1] - The new treatment option is expected to provide safer and more convenient choices for patients with advanced hepatocellular carcinoma [1]

Investment Rating - The report assigns a "Buy" rating to China Biologic Products (1177 HK) with a target price of HK$4.80, indicating a potential upside of 36.8% from the current price of HK$3.51 [4]. Core Insights - The company reported a strong performance in Q3 2024, with revenue increasing by 14.3% year-on-year to RMB 5.47 billion, driven by the rapid growth of biosimilars and new products [1]. - Adjusted net profit surged by 58.0% to RMB 600 million, exceeding expectations [1]. - Management maintains a double-digit revenue growth guidance for the full year, with specific sales expectations for 2024 including RMB 2 billion from biosimilars and over RMB 500 million from Yilishu [1]. - The company is set to acquire control of Haorunbo (688656 CH), marking its entry into the immunodiagnostics sector, with a planned acquisition of up to 55.00% of the shares [2]. - The acquisition price is set at RMB 33.74 per share, representing a 5% premium over the last trading day before suspension [2]. Summary by Sections Q3 Performance - Q3 2024 revenue reached RMB 5.47 billion, a 14.3% increase year-on-year, attributed to the growth of biosimilars and new product launches [1]. - Adjusted net profit rose by 58.0% to RMB 600 million, surpassing expectations [1]. Future Growth Prospects - The company expects biosimilars to generate RMB 2 billion in sales in 2024, with specific products like Bevacizumab and Trastuzumab projected to contribute RMB 700-800 million and around RMB 500 million, respectively [1]. - New product launches in 2025 are anticipated to further enhance revenue, with the first-year sales of the biosimilar Pertuzumab expected to exceed RMB 800 million [1]. Acquisition Strategy - The acquisition of Haorunbo will provide China Biologic Products with control over a company focused on immunodiagnostics, enhancing its product portfolio in respiratory and autoimmune disease areas [2]. - Haorunbo reported revenues of RMB 394 million and a net profit of RMB 43.3 million in 2023, with commitments from original shareholders for future profit guarantees [2].

Core Insights - China Biopharmaceutical (01177.HK) reported a strong performance in Q3, driven by the recovery of the pharmaceutical industry and accelerated R&D, production, and sales [1] - The company achieved approximately RMB 21.35 billion in revenue for the first three quarters, reflecting a year-on-year growth of about 11.9% [1] - The net profit attributable to shareholders for the first three quarters was approximately RMB 4.17 billion, showing a significant year-on-year increase of about 134.9% [1] Revenue Performance - Q3 revenue reached approximately RMB 5.47 billion, marking a year-on-year growth of about 14.3% [1] - The management highlighted that several innovative products, including Bevacizumab, Rituximab, and Trastuzumab, have been rapidly gaining market traction, contributing significantly to revenue growth [2] Profitability - The adjusted net profit attributable to shareholders for the first three quarters was approximately RMB 2.14 billion, with a year-on-year increase of about 23.7% [1] - In Q3, the net profit attributable to shareholders was approximately RMB 1.15 billion, reflecting a year-on-year growth of about 123.4% [1] Innovation and Future Outlook - The company has entered a phase of intensive innovation product harvest, having received approvals for four innovative products this year, including three Class 1 innovative drugs [1] - Future focus areas for China Biopharmaceutical include oncology, liver disease, respiratory, and surgical/pain management, with an emphasis on accelerating product launch processes [2]

本文为IPO早知道原创 作者｜罗宾 微信公众号｜ipozaozhidao 已启动C2轮融资。 礼新医药创始人、董事长兼首席执行官秦莹博士表示："礼新医药自创立以来，一直坚持源头自主创 新，聚焦肿瘤微环境，专注于开发研发肿瘤特异性靶向ADC和免疫调节大分子创新药物，已建立了 一套完整覆盖从临床前直至临床III期的拥有自主知识产权并具有全球竞争力的差异化创新药管线。我 们将不负众望，加快推进LM-302和LM-108两个后期临床管线，争取早日实现产品上市。同时， 持续产出聚焦于肿瘤免疫及肿瘤微环境领域内尚未满足的治疗需求的早期源头创新管线，并继续积极 探索与各种伙伴以及各界展开多元化的紧密合作，通过BD合作进一步提升公司自我造血能力。" 中国生物制药有限公司董事会主席谢其润表示："中国生物制药已上市了安罗替尼等众多重要的肿瘤 产品，并且正持续不断地投入创新药研发与合作。我们一直关注肿瘤免疫治疗和ADC药物的研发进 展，礼新医药是一家聚焦于肿瘤免疫及肿瘤微环境领域的创新药公司，其差异化的创新管线布局、扎 实的GPCR多次跨膜蛋白抗体发现平台、双抗技术平台和ADC技术平台、都给我们留下了深刻的印 象。我们坚定看好礼新 ...

Investment Rating - The report recommends a "Buy" rating for China Biopharmaceuticals (1177.HK) for the first time [2][5]. Core Views - China Biopharmaceuticals is a leading player in the Chinese pharmaceutical industry, with expected continuous improvement in profit margins. The company reported a revenue of 26.199 billion yuan in 2023, a decrease of 8.97%, primarily due to the sale of its stake in Zhengda Qingdao and the impact of medical anti-corruption measures. However, the revenue from continuing operations showed a slight increase of 0.7% year-on-year [3][5]. - The company is advancing its innovation and internationalization strategies across four core business segments: oncology, liver disease, respiratory, and surgical/pain management. The R&D expenditure in 2023 was 4.403 billion yuan, accounting for approximately 16.8% of revenue, with over 77% of this investment directed towards innovative and biological drugs [3][5][19]. Summary by Sections Company Overview - China Biopharmaceuticals is a key player in the Chinese pharmaceutical sector, with a stable shareholding structure and absolute control over its core subsidiaries. The company is part of the Charoen Pokphand Group, which has a strong global presence [10][13]. Financial Performance - The company’s revenue for 2023 was 26.199 billion yuan, reflecting a decline of 8.97%. However, the first half of 2024 saw a revenue increase of 11.1%, reaching 15.874 billion yuan, indicating a return to positive growth [3][15]. - The adjusted net profit for the first half of 2024 was 1.540 billion yuan, up 14.0% year-on-year, signaling a potential turning point in profitability [3][15]. Business Segments - The oncology segment is expected to drive significant growth, with key products like Anlotinib and innovative therapies showing strong market potential. The company anticipates that Anlotinib will achieve a peak sales target of 10 billion yuan [21]. - The liver disease segment is also promising, with products like Magnesium Isoglycyrrhizinate expected to synergize with oncology offerings. The company has several products in late-stage clinical trials for NASH [19][21]. - The respiratory segment is positioned for growth, with inhaled formulations like Budesonide showing strong sales potential. The company has multiple innovative candidates in late-stage clinical trials [19][21]. - The surgical/pain management segment is supported by products like Flurbiprofen Gel, which is expected to contribute to revenue growth [19][21]. R&D and Innovation - The company is committed to expanding its R&D efforts, with a focus on innovative drugs. In 2023, R&D expenses reached 4.403 billion yuan, with a significant portion allocated to innovative drug development [19][21]. - The company plans to launch over 10 innovative products in the next three years, further enhancing its competitive position in the market [19][21].

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 3.79, indicating a potential upside of 15.0% from the current price of HKD 3.30 [3][4]. Core Insights - The company is entering a harvest period for its innovative transformation, with a focus on oncology and a gradual improvement in product value [2]. - The risk from centralized procurement has been largely mitigated, and the company continues to see growth in its innovative products, achieving a revenue of HKD 158.7 billion in the first half of 2024, representing a year-on-year increase of 11.1% [2][3]. - The oncology segment generated revenue of HKD 53.6 billion, up 19.5%, accounting for 33.8% of total revenue [2]. Summary by Sections Financial Performance - The company reported a gross profit of HKD 130.3 billion, with a gross margin of 82.1%, reflecting an increase of 11.5% [2]. - Research and development expenses amounted to HKD 25.8 billion, a rise of 10.9%, with an expense ratio of 17% [2]. - The net profit attributable to shareholders reached HKD 30.2 billion, a significant increase of 139.7%, while the adjusted net profit was HKD 15.4 billion, up 14.0% [2]. Product Pipeline and Innovation - The company has accelerated its innovation efforts, focusing on four key areas: oncology, liver disease, respiratory, and surgical analgesia [3]. - In the first half of the year, the company received approval for three innovative drugs and one biosimilar, enhancing its product offerings [3]. - The oncology pipeline is particularly strong, with multiple drugs in clinical research and expected approvals that will drive future revenue growth [3]. Market Position and Valuation - The company has a market capitalization of HKD 620.1 billion and has issued 18.79 billion shares [4]. - The report uses a discounted cash flow (DCF) model for valuation, with a weighted average cost of capital (WACC) of 9.4% and a perpetual growth rate of 3% [3].